LBTSF News and Press, Almirall Sa Ord

Lebrikizumab is recommended by NICE for the use in moderate to severe Atopic Dermatitis in patients 12 years and over when their condition has not responded to at least 1 systemic immunosuppressant, or when these treatments are not suitable Following approval of the European Commission (Octob...

2024-07-03 10:51:31 ET More on Absci Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Fin...

Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...

Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...

2024-05-13 14:04:09 ET Almirall, S.A. (LBTSF) Q1 2024 Results Conference Call May 13, 2024 04:00 AM ET Company Participants Pablo Divasson - Director, IR and Corporate Communications Carlos Gallardo - Chairman and CEO Karl Ziegelbauer - Chief Scientific Officer ...

Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...

Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon re...

2024-03-11 05:53:32 ET Eli Lilly ( NYSE: LLY ) on Sunday reported robust efficacy data from a study for its atopic dermatitis drug, lebrikizumab.... Read the full article on Seeking Alpha For further details see: Eli Lilly eczema drug shows robust efficacy in peo...

2024-02-19 17:55:04 ET Almirall, S.A. (LBTSF) Q4 2023 Earnings Conference Call February 19, 2024, 04:00 AM ET Company Participants Pablo Divasson - Director, IR and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - CFO Karl Ziegelba...

Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...